Regeneron files Eylea for DME indication

Share this article:

Regeneron announced today that the FDA has accepted Eylea's supplemental Biologics License Application for the treatment of diabetic macular edema (DME). The goal for a standard review of an sBLA is 10 months from submission, for a target action date of August 18, 2014. The submission is based off positive results from the company's Phase 3 VIVID and VISTA trials.

Eylea was approved in the US for the treatment of neovascular (wet) age-related macular degeneration (AMD) in November 2011 and for macular edema following central retinal vein occlusion (CRVO) in September 2011. Bayer and Regeneron are collaborating on the global development of the drug. Regeneron holds exclusive rights in the US, while Bayer has exclusive marketing rights ex-US. Both companies will share equal profits from sales of Eylea except for Japan, where Regeneron receives a royalty.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters